The 25th report on survey of the adverse reaction to radiopharmaceuticals (The 28th survey in 2002)

The survey in the title involves occasions of adverse reactions and drug defects of radiopharmaceuticals and its 28th one in 2002 (April 1, 2002-March 31, 2003) is reported herein. The survey was conducted by questionnaire to 1,211 facilities, of which 1,033 (85.3%) answered. Adverse reaction (37 cases/1,395,928=0.0027% occasion) and drug defect (1, 0.0001%) were reported from 32 facilities: They were 0.0017-0.0027% and 0.0001-0.0005%, respectively, after 1998. Frequent occasion of adverse reaction was seen in 131I-methyl-norcholesterol (0.2039%), 99mTc-PYP (0.0610%) and 131I-sodium hippurate (0.0505%). Occasion of the adverse reaction of other drugs was less than 0.05%. The first one (131I-methyl-norcholesterol) was considered to be due to the ingredient, ethanol. As well, one case of a serious adverse reaction that required the intense life saving treatment was reported for intravenous 99mTc-HMDP. The drug defect was due to the abnormal distribution (1 case). A preliminary examination of PET radiopharmaceuticals was conducted, of which results were: 35,711 administrations of 15O- and 18F-labeled compounds in 39 facilities in 86.7% answering rate. (N.I.)